国循発ベンチャー、1400万ドルを調達 パー・セラピューティクス、PAHの治療法開発へ
MediaPortfolio Companies
国循発ベンチャー、1400万ドルを調達 パー・セラピューティクス、PAHの治療法開発へ
July 29, 2025

Press Release
Portfolio Companies
Crystalys Therapeutics Advances Phase 3 Trials of Dotinurad for the Treatment of Gout with Dosing of First Patient
San Diego, October 21, 2025

Press Release
Portfolio Companies
AN Venture Partner’s New Portfolio Company, Crystalys Therapeutics Launches with $205M Series A Financing to Advance Next-Generation Gout Treatment
San Diego, September 30, 2025
